Movatterモバイル変換

[0]ホーム
URL:

MX2023009581A - Compositions and methods for treating her2 positive cancers. - Google Patents

Compositions and methods for treating her2 positive cancers.

Info

Publication number
MX2023009581A
MX2023009581AMX2023009581AMX2023009581AMX2023009581AMX 2023009581 AMX2023009581 AMX 2023009581AMX 2023009581 AMX2023009581 AMX 2023009581AMX 2023009581 AMX2023009581 AMX 2023009581AMX 2023009581 AMX2023009581 AMX 2023009581A
Authority
MX
Mexico
Prior art keywords
receptor
methods
compositions
her2 positive
positive cancers
Prior art date
Application number
MX2023009581A
Other languages
Spanish (es)
Inventor
Carl Alexander Kamb
Han Xu
Agnes Hamburger
Julyun Oh
Yuta Ando
Jee Young Mock
Original Assignee
A2 Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics IncfiledCriticalA2 Biotherapeutics Inc
Publication of MX2023009581ApublicationCriticalpatent/MX2023009581A/en

Links

Classifications

Landscapes

Abstract

The disclosure relates to immune cells comprising a dual receptor system responsive to loss of heterozygosity in a target cell, and methods of making and using same. The first receptor comprises activator receptor specific to a HER2 antigen, and the second receptor comprises an inhibitory receptor specific to an antigen lost in cancer but not wild type cells, that inhibits activation of the immune cells by the first receptor.
MX2023009581A2021-02-162022-02-16Compositions and methods for treating her2 positive cancers.MX2023009581A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US202163149952P2021-02-162021-02-16
PCT/US2022/016582WO2022177979A1 (en)2021-02-162022-02-16Compositions and methods for treating her2 positive cancers

Publications (1)

Publication NumberPublication Date
MX2023009581Atrue MX2023009581A (en)2023-08-23

Family

ID=82931150

Family Applications (1)

Application NumberTitlePriority DateFiling Date
MX2023009581AMX2023009581A (en)2021-02-162022-02-16Compositions and methods for treating her2 positive cancers.

Country Status (10)

CountryLink
US (2)US11730764B2 (en)
EP (1)EP4294828A4 (en)
JP (1)JP2024507129A (en)
KR (1)KR20230147109A (en)
CN (1)CN117597358A (en)
AU (1)AU2022221606A1 (en)
CA (1)CA3207958A1 (en)
IL (1)IL304857A (en)
MX (1)MX2023009581A (en)
WO (1)WO2022177979A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2024059733A2 (en)*2022-09-142024-03-21Fred Hutchinson Cancer CenterChimeric antigen receptors binding nectin-4
CN116376844B (en)*2023-05-312023-08-11四川大学华西医院 CAR-T targeting HER2-positive tumors comprising SHP2 SH2 domain and its preparation method and application
WO2025030141A1 (en)*2023-08-022025-02-06A2 Biotherapeutics, Inc.Compositions and methods for treating cancers with hla-a*03 loss of expression

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4690915A (en)1985-08-081987-09-01The United States Of America As Represented By The Department Of Health And Human ServicesAdoptive immunotherapy as a treatment modality in humans
US6534055B1 (en)1988-11-232003-03-18Genetics Institute, Inc.Methods for selectively stimulating proliferation of T cells
US5858358A (en)1992-04-071999-01-12The United States Of America As Represented By The Secretary Of The NavyMethods for selectively stimulating proliferation of T cells
US6905680B2 (en)1988-11-232005-06-14Genetics Institute, Inc.Methods of treating HIV infected subjects
US6352694B1 (en)1994-06-032002-03-05Genetics Institute, Inc.Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5585362A (en)1989-08-221996-12-17The Regents Of The University Of MichiganAdenovirus vectors for gene therapy
US5350674A (en)1992-09-041994-09-27Becton, Dickinson And CompanyIntrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en)1994-06-032007-02-13Genetics Institute, LlcMethods for selectively stimulating proliferation of T cells
US6692964B1 (en)1995-05-042004-02-17The United States Of America As Represented By The Secretary Of The NavyMethods for transfecting T cells
US7067318B2 (en)1995-06-072006-06-27The Regents Of The University Of MichiganMethods for transfecting T cells
EP1235842A4 (en)1999-10-152003-04-23Univ Massachusetts GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE
US6326193B1 (en)1999-11-052001-12-04Cambria Biosciences, LlcInsect control agent
US7572631B2 (en)2000-02-242009-08-11Invitrogen CorporationActivation and expansion of T cells
US6867041B2 (en)2000-02-242005-03-15Xcyte Therapies, Inc.Simultaneous stimulation and concentration of cells
US6797514B2 (en)2000-02-242004-09-28Xcyte Therapies, Inc.Simultaneous stimulation and concentration of cells
HK1047770A1 (en)2000-02-242003-03-07Xcyte Therapies, Inc.Simultaneous stimulation and concentration of cells
AU2001275474A1 (en)2000-06-122001-12-24Akkadix CorporationMaterials and methods for the control of nematodes
US7745140B2 (en)2002-01-032010-06-29The Trustees Of The University Of PennsylvaniaActivation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20030170238A1 (en)2002-03-072003-09-11Gruenberg Micheal L.Re-activated T-cells for adoptive immunotherapy
CA2559955C (en)2004-03-152016-02-16City Of HopeMethods and compositions for the specific inhibition of gene expression by double-stranded rna
EP1765988B1 (en)2004-05-272017-09-20The Trustees of The University of PennsylvaniaNovel artificial antigen presenting cells and uses therefor
CA3084919A1 (en)2012-02-222013-08-29The Trustees Of The University Of PennsylvaniaCompositions and methods for generating a persisting population of t cells useful for the treatment of cancer
FI3597749T3 (en)2012-05-252023-10-09Univ California METHODS AND COMPOSITIONS FOR RNA-DIRECTED MODIFICATION OF TARGET DNA AND RNA-DIRECTED MODULATION OF TRANSCRIPTION
US8697359B1 (en)2012-12-122014-04-15The Broad Institute, Inc.CRISPR-Cas systems and methods for altering expression of gene products
JP2016505256A (en)2012-12-122016-02-25ザ・ブロード・インスティテュート・インコーポレイテッ CRISPR-Cas component system, method and composition for sequence manipulation
ES2576126T3 (en)2012-12-122016-07-05The Broad Institute, Inc. Modification by genetic technology and optimization of improved enzyme systems, methods and compositions for sequence manipulation
CN105246504A (en)2013-03-152016-01-13纪念斯隆-凯特琳癌症中心 Compositions and methods for immunotherapy
DK3071222T3 (en)2013-11-212020-11-16Ucl Business Ltd CELL
CA3029121A1 (en)2016-06-292018-01-04Crispr Therapeutics AgCompositions and methods for gene editing
EP3263595A1 (en)2016-06-302018-01-03Medizinische Hochschule HannoverFusion protein for use in the treatment of hvg disease
KR102742220B1 (en)*2017-09-192024-12-17더 유니버시티 오브 브리티쉬 콜롬비아 Anti-HLA-A2 antibodies and methods of use thereof
PT3688155T (en)2017-09-282023-04-11Gavish Galilee Bio Appl Ltd A UNIVERSAL PLATFORM TO PREPARE AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)
CN110484507B (en)*2018-01-312023-10-13温州医科大学 Preparation technology of a new chimeric antigen receptor T cell targeting tumor Her2
TW202434719A (en)*2018-08-102024-09-01國立大學法人京都大學Method for producing cd3-positive cells
CA3114736A1 (en)*2018-09-282020-04-02Immpact-Bio Ltd.Methods for identifying activating antigen receptor (acar)/inhibitory chimeric antigen receptor (icar) pairs for use in cancer therapies
IL316764A (en)*2019-04-032025-01-01Prec Biosciences IncGenetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
WO2021030149A1 (en)2019-08-092021-02-18A2 Biotherapeutics, Inc.Cell-surface receptors responsive to loss of heterozygosity
WO2021030153A2 (en)2019-08-092021-02-18A2 Biotherapeutics, Inc.Engineered t cell receptors and uses thereof
US20220289842A1 (en)2019-08-202022-09-15Senti Biosciences, Inc.Chimeric inhibitory receptor
US20220389075A1 (en)2019-11-122022-12-08A2 Biotherapeutics, Inc.Engineered t cell receptors and uses thereof
CA3161112A1 (en)*2019-12-112021-06-17Carl Alexander KambLilrb1-based chimeric antigen receptor
WO2021222576A1 (en)2020-05-012021-11-04A2 Biotherapeutics, Inc.Pag1 fusion proteins and methods of making and using same
KR20230083281A (en)*2020-09-042023-06-09임팩트 바이오 유에스에이 인코포레이티드 Bicistronic inhibitory chimeric antigen receptor (iCAR)/activating chimeric antigen receptor (aCAR) constructs for use in cancer therapy
CA3199897A1 (en)*2020-11-242022-06-02Carl Alexander KambAdoptive cell therapy for treatment of cancer associated with loss of heterozygosity
CN117642510A (en)*2021-07-012024-03-01宁波茂行生物医药科技有限公司 Universal CAR-T cells targeting HER2 and preparation methods thereof

Also Published As

Publication numberPublication date
KR20230147109A (en)2023-10-20
EP4294828A4 (en)2025-02-26
US20220339194A1 (en)2022-10-27
US11730764B2 (en)2023-08-22
AU2022221606A9 (en)2025-01-16
EP4294828A1 (en)2023-12-27
CN117597358A (en)2024-02-23
IL304857A (en)2023-10-01
JP2024507129A (en)2024-02-16
AU2022221606A1 (en)2023-08-24
CA3207958A1 (en)2022-08-25
US20240075067A1 (en)2024-03-07
WO2022177979A1 (en)2022-08-25

Similar Documents

PublicationPublication DateTitle
MX2023009581A (en)Compositions and methods for treating her2 positive cancers.
BR112022025295A2 (en) GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CANCER IMMUNOTHERAPY TARGETED CD70
ZA202400108B (en)A group of b7h3 monoclonal antibodies and medical use thereof
MX2023002041A (en) COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS.
BR112018006140A2 (en) antibody or antigen-binding portion thereof, pharmaceutical composition, and method for inhibiting cancer cell proliferation.
EP4442815A3 (en)Compositions and methods for treating egfr positive cancers
AU2018278730A1 (en)A novel anti-c-Met antibody and use thereof
MX2022005821A (en)Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70.
EP4501351A3 (en)Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
MX2022008638A (en)Bcma-directed cellular immunotherapy compositions and methods.
AU2021259346A8 (en)Compositions and methods of treating cancer with chimeric antigen receptors
MX2021012236A (en)Method for enhancing cellular immunotherapy.
PH12022550035A1 (en)Antibodies which bind to cancer cells and target radionuclides to said cells
MX2022000853A (en)Humanized anti-liv1 antibodies for the treatment of cancer.
MX2022005816A (en) THERAPY OF SOLID CD70+ TUMORS USING GENOMODIFIED T LYMPHOCYTES DIRECTED AT CD70.
ZA202305072B (en)Cd1a antibodies and uses thereof
CA3207182A1 (en)T cell therapy
WO2023077038A3 (en)Systems and methods to identify mhc-associated antigens for therapeutic intervention
WO2020084102A3 (en)Oncolytic virotherapy and immunotherapy
MX2025005903A (en)Compositions and methods for improved cancer treatment
BR112022013445A2 (en) NATURAL KILLER CELL MODIFICATION METHOD TO TARGET CD70-POSITIVE TUMORS
MX2024002390A (en) METHODS FOR GENERATING PRIMARY IMMUNE CELLS.
EP4559526A3 (en)Composition for regulating cancer cell division or differentiation comprising setdb1 or a setdb1 inhibitor
WO2023147019A3 (en)Compositions and methods for treating mesothelin positive cancers
EP4434541A3 (en)Antibodies specific to delta 1 chain of t cell receptor
[8]ページ先頭
©2009-2025 Movatter.jp